PH284 nasal spray demonstrated improvements to subjective feelings of hunger in cancer patients PH284 is the fifth pherine product candidate in Vistagen’s neuroscience pipeline with a positive efficacy signal SOUTH SAN FRANCISCO, Calif. / Jan 14, 2025 / Business Wire / Vistagen...Read more
CAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced positive results from a preclinical study on the company’s lead cell therapy product, ERNA-101, which is...Read more
Interim data from Cohort 4 expected Q1 2025 MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for...Read more
Application based on TROPION-Lung05 trial and supported by data from TROPION-Lung01 and TROPION-PanTumor01 trials Approval would mark the first for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan in lung cancer WILMINGTON, Del. / Jan 13, 2025 / Business Wire / AstraZeneca and Daiichi...Read more
The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2 The test helps differentiate a B-cell cancer from a normal, reactive immune...Read more
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option TOKYO and CAMBRIDGE, Mass., Jan. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and...Read more
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Finch Therapeutics | 8.80 488.89 | $10.60 |
| Agilent Technologies | 5.93 4.36 | $142.03 |
| argenx | 4.99 0.74 | $675.39 |
| Acadia Healthcare | 4.41 11.12 | $44.06 |
| Sarepta Therapeutics | 4.19 3.54 | $122.62 |
| iRhythm Technologies | 3.94 4.17 | $98.53 |
| Accolade | 3.41 98.98 | $6.85 |
| Medtronic | 3.31 4.05 | $85.11 |
| Praxis Precision Medicines | 2.95 4.61 | $66.97 |
| DaVita | 2.93 1.87 | $159.99 |
| Evaxion Biotech | 2.92 343.53 | $3.77 |
| Sonendo | 2.77 1,204.35 | $3.00 |
| Ascendis Pharma | 2.76 2.06 | $136.80 |
| BioNTech | 2.75 2.42 | $116.49 |
| SANUWAVE Health | 2.75 10.48 | $29.00 |
| TG Therapeutics | 2.74 9.90 | $30.42 |
| Veradigm | 2.69 39.50 | $9.50 |
| Integer | 2.50 1.85 | $137.65 |
| Company | Volume | Last Trade |
|---|---|---|
| Eterna Therapeutics | 583,669,367 | $0.94 |
| P3 Health Partners | 169,089,826 | $0.23 |
| Tonix Pharmaceuticals | 59,986,556 | $0.24 |
| Quantum-Si | 18,231,376 | $2.04 |
| Soligenix | 15,112,401 | $2.69 |
| Senseonics | 11,613,509 | $0.75 |
| CNS Pharmaceuticals | 11,514,666 | $0.11 |
| Walgreens Boots Alliance | 11,269,257 | $12.28 |
| Aditxt | 11,173,850 | $0.14 |
| Mustang Bio | 10,239,522 | $0.14 |
| Conduit Pharmaceuticals | 9,328,147 | $0.10 |
| Intra-Cellular Therapies | 8,958,700 | $127.06 |
| Mobile-health Network Solutions | 8,161,396 | $0.37 |
| Phio Pharmaceuticals | 7,775,201 | $3.59 |
| Eyenovia | 6,775,784 | $0.09 |
| Iovance Biotherapeutics | 6,686,869 | $6.19 |
| Azitra | 6,646,191 | $0.49 |
| Mersana Therapeutics | 6,079,050 | $0.64 |
| Geron | 6,032,031 | $3.04 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
